SCHEMBL708371

SCHEMBL708371

COc1cc(OC)cc(C(=O)c2nc3cc(C(=O)O)ccc3n2CCc2ccccc2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 4/20 0.54
LMNA P02545 1/20 0.54
KDM4E B2RXH2 2/20 0.52
EHMT2 Q96KQ7 3/20 0.49
EHMT1 Q9H9B1 1/20 0.49
SUV39H1 O43463 1/20 0.49
PRMT1 Q99873 1/20 0.49
ALDH1A1 P00352 1/20 0.46
RECQL P46063 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
PIN1 Q13526 1/20 0.46
PTGER4 P35408 5/20 0.46
HCAR3 P49019 1/20 0.46
THRB P10828 1/20 0.46
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
ENPP2 Q13822 1/20 0.44
JAK2 O60674 1/20 0.43
JAK1 P23458 1/20 0.43
TYK2 P29597 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL707552 0.82 POLB (0.50) POLBLMNAKDM4EALDH1A1RECQL
SCHEMBL708379 0.80 POLB (0.51) POLBLMNAKDM4EALDH1A1RECQL
SCHEMBL707130 0.80 PPARG (0.54) POLBLMNAKDM4EPIN1
SCHEMBL707714 0.79 LPAR1 (0.51) POLBLMNAKDM4EALDH1A1RECQL
SCHEMBL19987366 0.79 HSD17B10 (0.59) POLBKDM4EEHMT2EHMT1PTGER4
SCHEMBL709120 0.77 POLB (0.49) POLBLMNAKDM4EALDH1A1RECQL
SCHEMBL708380 0.75 LPAR1 (0.51) POLBKDM4EALDH1A1
SCHEMBL705825 0.71 SRD5A2 (0.57) POLBKDM4EALDH1A1MEN1KMT2A
SCHEMBL1285053 0.71 LPAR1 (0.44) POLBKDM4EEHMT2ALDH1A1
SCHEMBL706447 0.71 LPAR1 (0.52) POLBKDM4EALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1553075-B1 LPA RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO (JP) 2013-08-14 EP disclosed
EP-2565178-A1 LPA Receptor Antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2013-03-06 EP disclosed
US-20120088782-A1 LPA RECEPTOR ANTAGONIST ONO PHARMACEUTICAL CO., LTD. (JP) 2012-04-12 US disclosed
US-8124645-B2 LPA receptor antagonist ONO PHARMACEUTICAL CO., LTD. (JP) 2012-02-28 US disclosed
US-7820682-B2 LPA receptor antagonist ONO PHARMACEUTICAL CO., LTD. (JP) 2010-10-26 US disclosed
US-20100249157-A2 LPA RECEPTOR ANTAGONIST ONO PHARMACEUTICAL CO., LTD. (JP) 2010-09-30 US disclosed
US-20080293764-A1 LPA RECEPTOR ANTAGONIST ONO PHARMACEUTICAL CO., LTD. 2008-11-27 US disclosed
US-20060148830-A1 Lpa receptor antagonist ONO PHARMACEUTICAL CO., LTD. 2006-07-06 US disclosed
EP-1553075-A1 LPA RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2005-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293764-A1 LPA RECEPTOR ANTAGONIST LPAR1, LPAR2, LPAR4 POLB 1235/4885LMNA 1108/4885KDM4E 4132/4885
US-20100249157-A2 LPA RECEPTOR ANTAGONIST LPAR1, LPAR2, LPAR4 POLB 1235/4885LMNA 1108/4885KDM4E 4132/4885
US-20120088782-A1 LPA RECEPTOR ANTAGONIST LPAR1, LPAR2, LPAR4 POLB 1235/4885LMNA 1108/4885KDM4E 4132/4885
US-20060148830-A1 Lpa receptor antagonist LPAR1, LPAR2, LPAR4 POLB 1235/4885LMNA 1108/4885KDM4E 4132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.